Clinically Relevant Progestins Regulate Neurogenic and Neuroprotective Responses \textit{in Vitro} and \textit{in Vivo}

Lifei Liu, Liqin Zhao, Hongyun She, Shuhua Chen, Jun Ming Wang, Charisse Wong, Kelsey McClure, Regine Sitruk-Ware, and Roberta Diaz Brinton

Program in Neuroscience (L.L., R.D.B.), Department of Pharmacology and Pharmaceutical Sciences (L.Z., H.S., C.W., K.M., R.D.B.), University of Southern California, School of Pharmacy Pharmaceutica Sciences Center, Los Angeles, California 90033; Department of Pathology (J.M.W.), University of Mississippi Medical Center, Jackson, Mississippi 39216; and Center of Biomedical Research (R.S.-W.), Population Council, Rockefeller University, New York, New York 10065

Previously, we demonstrated that progesterone ($P_4$) promoted adult rat neural progenitor cell (rNPC) proliferation with concomitant regulation of cell-cycle gene expression via the $P_4$ receptor membrane component/ERK pathway. Here, we report the efficacy of seven clinically relevant progestins alone or in combination with 17$\beta$-estradiol ($E_2$) on adult rNPC proliferation and hippocampal cell viability \textit{in vitro} and \textit{in vivo}. \textit{In vitro} analyses indicated that $P_4$, norgestimate, Nestorone, norethynodrel, norethindrone, and levonorgestrel (LNG) significantly increased in rNPC proliferation, whereas norethindrone acetate was without effect, and medroxyprogesterone acetate (MPA) inhibited rNPC proliferation. Proliferative progestins \textit{in vitro} were also neuroprotective. Acute \textit{in vivo} exposure to $P_4$ and Nestorone significantly increased proliferating cell nuclear antigen and cell division cycle 2 expression and total number of hippocampal 5-bromo-2-deoxyuridine (BrdU)-positive cells, whereas LNG and MPA were without effect. Mechanistically, neurogenic progestins required activation of MAPK to promote proliferation. $P_4$, Nestorone, and LNG significantly increased ATP synthase subunit $\alpha$ (complex V, subunit $\alpha$) expression, whereas MPA was without effect. In combination with $E_2$, $P_4$, Nestorone, LNG, and MPA significantly increased BrdU incorporation. However, BrdU incorporation induced by $E_2$ plus LNG or MPA was paralleled by a significant increase in apoptosis. A rise in Bax/Bcl-2 ratio paralleled apoptosis induced by LNG and MPA. With the exception of $P_4$, clinical progestins antagonized $E_2$-induced rise in complex V, subunit $\alpha$. These preclinical translational findings indicate that the neurogenic response to clinical progestins varies dramatically. Progestin impact on the regenerative capacity of the brain has clinical implications for contraceptive and hormone therapy formulations prescribed for pre- and postmenopausal women. \textit{(Endocrinology} \textit{151: 5782–5794, 2010)}

It is increasingly clear that gonadal hormone function extends well beyond reproduction (1–3). In brain, progesterone ($P_4$) exerts multiple nonreproductive functions including regulating mood, inflammation, bioenergetics, neural plasticity, cognition, and recovery from traumatic brain injury (1, 2, 4–6). Clinically, $P_4$ and related synthetic progestins have been widely used as therapeutics for fertility, contraception, and hormone replacement therapy (1, 2, 7–10). The majority of progestins are derived from three tetracyclic structures: pregnane, estrane, and gonane and have varying degrees of specificity for $P_4$ receptors (PRs) (Fig. 1) (9, 10). Recently, a newer class of progestins, the 19-norprogesterone molecules, has been developed with improved progestational activity with little to no androgenic activity and used for contraception and hormone therapy (11).

Abbreviations: AR, Androgen receptor; bFGF, basic fibroblast growth factor; BrdU, 5-bromo-2-deoxyuridine; BW, body weight; CDC2, cell division cycle 2; Cdk1, cyclin dependent kinase 1; CVa, complex V, subunit $\alpha$; $E_2$, 17$\beta$-estradiol; FACS, fluorescence-activated cell sorting; GR, glucocorticoid receptor; LDH, lactate dehydrogenase; LNG, levonorgestrel; MPA, medroxyprogesterone acetate; NE, neuroprotective efficacy; NETA, NET acetate; NGM, norgestimate; nPR, nuclear PR; OVX, ovariectomized; $P_4$, progesterone; PCNA, proliferating cell nuclear antigen; PGRMC-1, PR membrane component 1; PR, $P_4$ receptor; rNPC, rat neural progenitor cell; SAR, structure-activity relationship; TUNEL, terminal deoxynucleotidyltransferase-mediated 2’-deoxyuridine 5’-triphosphate nick end labeling.
Although the effect of progestins on the reproductive system has been extensively studied, their impact on central nervous system function, particularly adult neurogenesis and cell viability, remains largely unexplored (1). The generation of new neurons or neurogenesis in the two proliferative zones of the brain, the subgranular zone of the hippocampus and the subventricular zone of the cerebral ventricles, is the principle regenerative strategy of the adult brain. In parallel, cellular viability can be a predictive indicator of the health of newly generated and existing cells. In this study, we selected seven clinically relevant progestins as representative of three different classes of progestins to determine their effects on neural progenitor proliferation and neuronal viability (Fig. 1): one with pregnane structure [methyltestosterone acetate (MPA)], one with 19-norprogesterone structure (Nestorone), three with estrane structure [norethindrone (NET), NET acetate (NETA), and norethynodrel], and two with gonane structure [levonorgestrel (LNG) and norgestimate (NGM)], and the estranes, NET, NETA, and norethynodrel.

Materials and Methods

Chemicals

P₄, NET, NETA, ORG 31710, norethynodrel, LNG, MPA, and NGM were purchased from Steraloids (Newport, RI). Nestorone was provided by Sitruk-Ware (Rockefeller University and Population Council, New York, NY).

PR, androgen receptor (AR), and glucocorticoid receptor (GR) competitive binding

The binding affinities of tested progestins to PR, AR, and GR were determined by fluorescent polarization competitive binding assays using purified baculovirus-expressed human PR/AR/GR and fluorescent P₄/androgen/glucocorticoid ligand PL Red (Invitrogen, Grand Island, NY) as described before (7, 13), respectively. Polarization values were determined using GENios Pro microplate reader (Tecan, San Jose, CA) and plotted against the logarithm of the concentrations of test compounds. IC₅₀ values were determined by nonlinear least-squares analysis.

Culture of rat neural progenitor cells (rNPCs)

Rat NPCs derived from adult rat dentate gyrus (gift from Fred Gage; Laboratory of Genetics, The Salk Institute, CA) were provided as cryopreserved cells. They were cultured as described previously (7, 13, 14) in DMEM/Hams F-12 medium (1:1; Omega Scientific, Tarzana, CA) with 1% penicillin/streptomycin/ampicillin (Invitrogen), supplemented with N2 (1%; Invitrogen) and basic fibroblast growth factor (bFGF) (20 ng/ml; Invitrogen) in a humidified incubator (37°C and 5% CO₂). Cells were plated at a density of 2 × 10⁴ cells/flask or 7.5–15 × 10⁴ cells/well on 96-well plates.

5-Bromo-2-deoxyuridine (BrdU) incorporation

Cell proliferation was determined by S phase incorporation of BrdU. After 4–6 h of starvation (medium without supplements), rNPCs were loaded with 10 μM BrdU in the presence or absence of bFGF and varying concentrations of P₄ or test progestins in unsupplemented maintenance medium for 1d. The rNPCs were then processed as described previously (7, 14). After subtracting the value of the blank (without BrdU loading), data were analyzed using a one-way ANOVA, followed by a Neuman-Keuls post hoc test.
Primary neuronal culture

Hippocampal neuronal cultures were prepared as previously described (13).

Glutamate exposure and neuronal viability

Hippocampal neuronal cultures grown on 96-well culture plates for 7d in vitro were pretreated with vehicle alone or test compounds, followed by exposure to 200 μM glutamate as previously described (13). After glutamate exposure, cultures were washed with N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid-buffered saline solution and replaced with fresh NBM containing the test compounds or combinations. Cultures were returned to the incubator and incubated for 24 h before analysis of neuronal viability using colorimetric lactate dehydrogenase (LDH) release in the media.

Animals

Use of animals was approved by the Institutional Animal Care and Use Committee at the University of Southern California (Protocol No. 10911). Embryonic d-18 fetuses derived from time-pregnant Sprague Dawley rats (Harlan, Indianapolis, IN) were used to obtain primary neuronal cultures for in vitro experiments. Ovariectomized (OVX) 3-month-old adult female Sprague Dawley rats (Harlan) were used for in vivo experiments. For progestin-only treatments (n = 5 per group), rats were sc injected 1 wk after ovariectomy with vehicle alone or P₄ [30 μg/kg body weight (BW)], Nestorone (30 μg/kg BW), LNG (30 μg/kg BW), and MPA (30 μg/kg BW), respectively, and 1 h later with 100 mg/kg BW BrdU injection. For E₂ and progestin combination treatments (n = 5 per group), rats were sc injected 1 wk after ovariectomy with either E₂ alone (30 μg/kg BW), or E₂ combined with P₄/Nestorone/LNG/MPA (30 μg/kg BW), or equivalent volume of sesame oil as vehicle control, respectively, and 1 h later with 100 mg/kg BW BrdU injection. For E₂ and progestin combination treatments (n = 5 per group), rats were sc injected 1 wk after ovariectomy with either E₂ alone (30 μg/kg BW), or E₂ combined with P₄/Nestorone/LNG/MPA (30 μg/kg BW), or equivalent volume of sesame oil as vehicle control, respectively, and 1 h later with 100 mg/kg BW BrdU injection. Doses of progestins were based on our previous and 1 h later with 100 mg/kg BW BrdU injection. Doses of progestins were based on our previous and 1 h later with 100 mg/kg BW BrdU injection. Doses of progestins were based on our previous and 1 h later with 100 mg/kg BW BrdU injection.

Western blot analyses

Hippocampal samples from progestin-treated rats were assessed for protein expression of proliferating cell nuclear antigen (PCNA) (1:500; Zymed Laboratories, San Francisco, CA) and cell division cycle 2 (CDC2) or cyclin dependent kinase 1 (Cdk1) (1:500; Novus Biologicals, Littleton, CO), mitochondria complex V, subunit α (CVα) (1:1000; MitoSciences, Inc., Eugene, OR), Bax (Bax) (1:1000; Cell Signaling Technology, Danvers, MA), and Bel-2 (50E3) (1:1000; Cell Signaling Technology) by Western blotting as previously described (7, 14). Relative amounts of protein expression were quantified by optical density analysis using UN-SCAN-IT gel automated digitizing system (Silk Scientific, Inc., Orem, UT).

Nuclei extraction and flow cytometry counting

Hippocampi were dissected from the fixed hemispheres using anatomical landmarks as described (15). Extracted hippocampi were homogenized and nuclei sample collected into a 1.5 ml microcentrifuge tube, washed four times using 200 μl of PBS, and then centrifuged for 10 min at 10,000 rpm. The pellet was then resuspended in 600 μl of PBS plus 0.5% Triton X-100, heated for 1 h at 75°C for epoxide retrieval, and incubated for 24 h at 4°C with primary mouse monoclonal anti-BrdU antibody (1:100, Ab12219; Abcam, Cambridge, MA) for BrdU+ cell count or with Clontech ApoAlert DNA Fragmentation Assay kit for DNA fragmentation [terminal deoxynucleotidyltransferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling (TUNEL)] detection. The number of nuclei was estimated by counting the propidium iodide, and the number of BrdU or TUNEL-labeled cells was detected using BD LSR II flow cytometer and BD FACSDiva software (BD Biosciences, San Jose, CA).

Statistical analyses

Data are presented as mean ± SEM and statistically significant differences determined by a one-way ANOVA followed by a Student-Newman-Keuls post hoc analysis.

Results

PR/GR/AR binding profiles of clinical progestins

To determine the binding profiles of tested progestins (Fig. 1) to nuclear PR (nPR), fluorescence polarization-based competitive binding assay was conducted (7, 13). Competitive binding assays were also conducted to determine their binding affinities to AR and GR, respectively. Data derived from the binding experiments are summarized in Table 1. The binding IC₅₀ values of P₄, 9.01 nM for PR, 119.3 nM for AR, and 6.51 nM for GR were consistent with those reported previously (2). Among these progestins, maximal binding affinity to nPR was exhibited by Nestorone (IC₅₀ = 5.07 nM), followed by LNG (IC₅₀ = 5.46 nM), MPA (IC₅₀ = 6.20 nM), NET (IC₅₀ = 14.32 nM), NETA (IC₅₀ = 38.92 nM), norethynodrel (IC₅₀ = 67.76 nM), and NETA (IC₅₀ = 482.80 nM). The low binding affinities of NETA and NGM were consistent with their prodrug properties, because they require conversion to NET and LNG, respectively, to exert progestational effects (11). With respect to AR binding affinity, LNG exhibited maximal binding affinity to AR (IC₅₀ = 2.90 nM), followed by MPA (IC₅₀ = 4.53 nM), NGM (IC₅₀ = 5.02 nM), NET (IC₅₀ = 18.02 nM), norethynodrel (IC₅₀ = 196.70 nM), and NETA (IC₅₀ = 876.90 nM). Nestorone did not bind to AR, consistent with previous reports indicating that Nestorone has little androgenic activity (16). Lastly, progestin binding to GR was as follows: MPA (IC₅₀ = 1.42 nM), Nestorone (IC₅₀ = 8.71 nM), LNG (IC₅₀ = 16.73 nM), NET (IC₅₀ = 97.84 nM), NETA (IC₅₀ = 202.70 nM), NGM (IC₅₀ = 287.10 nM), and norethynodrel (IC₅₀ = 1306.00 nM). Overall, results from these binding analysis confirmed previous reports and provided a direct comparison of binding affinities of tested progestins with PR, AR, and GR. Further, results...
indicated that clinical progestins have a complex binding profile and have multiple targets in the biological systems that are likely to impact outcomes in brain.

Clinical progestin regulation of rNPC proliferation in vitro

Our previous study demonstrated that P₄ increased rNPC proliferation in a dose-dependent manner (7). To determine whether progestins exhibited comparable efficacy on rNPC proliferation, BrdU chemiluminescence ELISA was conducted and compared with the proliferative efficacy of P₄ at the same concentration (Fig. 2). Results of these analyses indicated that at 24 h, NGM was more potent in promoting rNPC proliferation than P₄ at all concentrations, with minimal effective dose of 10⁻¹¹ M and a maximal effect of 40.4 ± 1.5% increase at 10⁻⁹ M (P < 0.001). Nestorone and P₄ were equally efficacious at their EC₁₀₀ concentrations, with both EC₁₀₀ values being 10⁻¹⁰ M. Norethynodrel induced a comparable effect with P₄ within the picomolar to low nanomolar range and was significantly (P < 0.005) more efficacious than P₄ at high nanomolar to micromolar range, with minimal effective dose at 10⁻¹¹ M and maximal effective effect (43.5 ± 3.7% increase) at 10⁻⁷ M. NETU induced a moderate effect in promoting rNPC proliferation but was less effective than P₄ with a minimally effective dose of 10⁻¹¹ M and a maximal effect was 21.8 ± 1.7% increase at 10⁻⁶ M. Similarly, LNG exhibited a minimally effective dose of 10⁻⁸ M and a maximal effect of 17.7 ± 0.8% at 10⁻⁷ M. NETA and ORG 31710 exerted no effect on rNPC proliferation at all concentrations except 10⁻⁵ M, a concentration at which rNPC proliferation was significantly inhibited (P < 0.05 and P < 0.01, respectively). Lastly, MPA significantly inhibited rNPC proliferation at multiple concentrations with maximal inhibition at 10⁻¹⁰ M to 10⁻⁵ M with rNPC proliferation reduced by 17.0 ± 1.3% (P < 0.05) and 17.8 ± 1.2% (P < 0.05), respectively.

Progestin-induced cell proliferation is dependent on ERK signaling pathway and independent of nPR

Previously we demonstrated that P₄-induced cell proliferation is an ERK signaling pathway-dependent process (7). To determine whether ERK activation was required for progestin-induced cell proliferation, BrdU chemiluminescence ELISA was conducted in the presence or absence of the MEK kinase inhibitor UO126 (Fig. 3A). Consistent with results in Fig. 2, at 10⁻⁸ M, both P₄ and Nestorone significantly increased BrdU incorporation by 14.6 and 16.4% compared with vehicle control, respectively (P < 0.0001 and P < 0.0001, respectively). At 10⁻⁸ M, LNG had no statistically significant effect, although a positive trend was observed, whereas MPA significantly inhibited BrdU incorporation (P < 0.05). Inhibition of ERK/MAPK signaling pathway by UO126 abolished P₄-induced cell proliferation (P < 0.0001), which replicated our previous findings (7), and completely inhibited the proliferative effects of Nestorone and LNG (P < 0.0001 and P < 0.05, respectively) with no effect observed on MPA-induced inhibition of cell proliferation. These data indicate that like P₄, Nestorone- induced, and LNG-induced cell proliferation require the ERK signaling pathway, whereas the inhibitory effect of MPA is independent of the ERK/MAPK signaling pathway.

Analysis of the structure-activity relationship (SAR) was conducted to determine structural molecular features required for proliferative efficacy of clinical progestins. The presence of an acetyl or hydroxyl group at the 17S-position of the D ring was favorable for rNPC proliferation, whereas a methyl group at the 6-position, whether it was in the R or S configuration, negatively impacted cell proliferation (Fig. 3B). A modification at the 10R-position or at the 13S-position had no effect on the proliferative capabilities of the molecule nor did the position of the
double bond between C-4 and C-5 or between C-5 and C-10. Interestingly, addition of a hydroxyl group at the C-17-position is known to eliminate the progestational effect of progestins, whereas acetylation of the C-17-OH can reverse this effect to render the progestins orally active. Addition of the 13-C ethyl group is positively associated with the highest progestational activity, consistent with findings that helix 12 Met909 is the key residue for PR activation by both testosterone-derived and P₄-derived progestins with a 13-methyl or a 13-ethyl substitutions.

**FIG. 2.** Progestin regulation of NPC proliferation. Rat NPCs were starved for 4 h before exposure to clinical progestins (10 × 10⁻¹² to 10 × 10⁻⁵ M) for 24 h. Cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used as vehicle control (1 × 10⁻⁶), and bFGF was used as positive control. At each concentration, the proliferative efficacies of progestins (solid lines) were compared against that of P₄ (dotted line). A–C, Effects of progestins that had greater proliferative efficacy relative to P₄. D and E, Progestins with lower proliferative efficacy relative to P₄. F–H, Progestins with no or antagonizing effects on cell proliferation. Data are derived from three independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control (mean ± SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.005; and ****, P < 0.001 vs. vehicle control.
Clinical progestins regulate neurogenic activity and cell viability in vivo

To determine the generalizability of in vitro findings to the in vivo condition, analyses of rNPC proliferation and cell viability were conducted in 3-month-old Sprague Dawley O VX female rats treated with selected progestins. Selection of progestins for in vivo testing was based on the requirement that the progestin exert both a significant increase in rNPC proliferation and neuroprotection. Among these progestins, Nestorone, norethynodrel, and LNG fulfilled these criteria. However, norethynodrel was not advanced to in vivo testing because of its aromatization in liver to form the potent estrogen ethinyl-estradiol (19) and thus potential involvement of ER in proliferative action in vivo could not be excluded. Although MPA exerted a decrease in both rNPC proliferation and neuroprotection, it was included for in vivo analysis based on its continued clinical use and its controversial effects in brain (5, 20, 21). In addition to FACS determination of total number of BrdU+ hippocampal cells, two cell cycle protein markers, PCNA, which is associated with transition through S phase, and CDC2 (CDK1), which is associated with transition through the mitotic M phase, were assessed (7, 14). Results of cell cycle protein expression as determined by Western blotting indicated that both P4 and Nestorone exerted significant neuroprotection (13). Dose-response analysis was conducted for each progestin (Fig. 4) with neuroprotective efficacy (NE) calculated as follows:

\[
NE = \frac{(V_{\text{sample}} - V_{\text{glutamate}})}{(V_{\text{control}} - V_{\text{glutamate}})}
\]

Consistent with previous findings (5, 18), P4 induced a significant \((P < 0.05)\) protective effect with a minimally effective concentration of \(10^{-11}\) M and maximal effect of 55.7 ± 13.3% at \(10^{-7}\) M. Nestorone induced comparable neuroprotective efficacy with that of P4, with a minimally effective concentration of \(10^{-11}\) M and a maximal effect of 57.0 ± 4.4% at \(10^{-7}\) M. Norethynodrel was more potent than P4, and its minimal effective concentration was \(10^{-11}\) M, a concentration at which it also exhibited maximal neuroprotection of 80.8 ± 1.8% \((P < 0.001)\). LNG induced comparable efficacy with P4, with a minimally effective concentration \(10^{-11}\) M, a concentration at which LNG also induced maximal neuroprotection of 39.6 ± 3.2% \((P < 0.001)\). In contrast, NGM was much less potent with neuroprotection at \(10^{-7}\) M, whereas both MPA and NET showed modest neuroprotection at \(10^{-11}\) M but were without effect at other concentrations. Similar to the results of clinical progestin regulation of rNPCs proliferation, no association was found between the neuroprotective efficacy of the progestins and their binding affinities to PR, AR, or GR.
significantly increased PCNA expression at the protein level ($P < 0.05$ and $P < 0.01$, respectively) (Fig. 5A), whereas LNG and MPA had no significant effect upon PCNA protein expression ($P = 0.15$ and $P = 0.08$, respectively) (Fig. 5A, top). CDC2 protein expression was significantly increased by $P_4$ and Nestorone ($P < 0.05$ and $P < 0.01$, respectively), whereas LNG and MPA had no significant effect on CDC2 protein expression ($P = 0.07$ and $P = 0.23$, respectively) (Fig. 5A, bottom).

To assess the total number of BrdU+ cells, the contralateral hippocampal hemisphere used for protein analysis was fixed and processed for FACS analysis. Total number of BrdU+ cells per each hippocampus was determined and normalized to that of vehicle control. Results were plotted as the percent increase in BrdU+ cell ratio compared with vehicle control (Fig. 5B). Results derived from FACS analysis indicated that $P_4$ and Nestorone significantly increased BrdU+ cell number ($P < 0.05$ and $P < 0.01$, respectively), whereas LNG induced a comparable increase in BrdU incorporation with $P_4$ but was not statistically significant ($P = 0.054$). Further, MPA, which inhibited rNPC proliferation in vitro, had no significant effect on rNPC proliferation in vivo. Results of FACS analyses are consistent with data derived from Western blot analyses.

Previous analyses demonstrated that $P_4$ increased cell viability by promoting mitochondrial function and reducing oxidative damage (4). As a marker of cell viability,
expression of the α-subunit of ATP synthase-complex V (CVα) of the mitochondrial oxidative phosphorylation pathway was assessed by Western blot analysis. Consistent with previous results (4), P4 significantly increased CVα expression in vivo by 1-to-2-fold ($P < 0.05$) (Fig. 5C). Nestorone and LNG also significantly increased CVα expression in vivo ($P < 0.01$ and $P < 0.05$ compared with vehicle control, respectively) (Fig. 5C), whereas MPA ex-
erated no significant effect on CVα expression level, although a trend toward a decrease was observed \((P = 0.18)\). One of the closely associated events of increased cell viability is decreased apoptosis. To determine the effects of progestins on apoptosis, Western blot analyses were conducted to determine the expression level of Bax, a mediator of apoptosis by translocating to the mitochondria to release apoptotic factors such as cytochrome c \((22)\), and Bcl-2, an antiapoptotic protein that is a key component of the neuroprotective effect of E2 \((22)\). Ratio of Bax to Bcl-2 was used as the indicator of \textit{in vivo} apoptotic activity, because it positively correlates with apoptosis. P₄ and Nestorone had no effect on the ratio of Bax/Bcl-2 expression, whereas LNG \((P < 0.05)\) and MPA \((P = 0.05)\) significantly increased Bax/Bcl-2 ratio consistent with its proapoptotic effect in uterus reported by other groups \((23-25)\). Together with previous results on CVα expression, the \textit{in vitro} neuroprotective efficacy of clinical progestins paralleled their efficacy \textit{in vivo} to induce markers of cell viability.

**Impact of clinical progestins in combination with E₂ on neurogenesis and cell viability \textit{in vivo}**

When used clinically for hormone replacement therapy/contraceptive therapy, progestins are administered in conjunction with an estrogen. To determine the impact of the combination of E₂ and clinical progestins on neurogenesis and cell viability \textit{in vivo}, young adult OVX female Sprague Dawley rats were divided into six groups and received sc injection with either E₂ alone \((30 \mu g/kg BW)\) or E₂ combined with either P₄, Nestorone, LNG, MPA \((30 \mu g/kg BW)\), or equivalent volume of sesame oil as vehicle control. Hippocampi were isolated 24 h later for Western blot analysis and flow cytometry to determine the impact of treatment on cell viability and neurogenesis, respectively.

Expression level of PCNA, which is associated with transition through S phase, was assessed to determine the impact of treatment groups on the entry into the cell cycle required for neurogenesis. Results of these analyses indicated that E₂ significantly increased PCNA expression at the protein level, and combination of E₂ and progestins were progestin dependent (Fig. 6A): E₂+Nestorone induced the greatest magnitude of PCNA expression \((P < 0.01)\), whereas E₂+P₄, E₂+LNG and E₂+MPA exhibited comparable increase in PCNA level \((P < 0.05)\). Further, E₂+Nestorone-induced PCNA expression was significantly greater when compared with E₂ alone \((P < 0.05)\). Entry into the cell cycle was confirmed by FACS analysis, which detected BrdU incorporation in the contralateral hippocampal hemisphere (Fig. 6B). Consistent with PCNA expression, E₂ and its combination with progestins significantly increased the BrdU+ cell population. In contrast to the effect of MPA \textit{in vitro}, where MPA inhibited rNPC proliferation, and \textit{in vivo}, where it had no effect on PCNA expression or BrdU incorporation as detected by FACS, the E₂+MPA group exhibited the greatest increase in the number of BrdU+ cells indicated by a significant 4-fold increase compared with vehicle control \((P < 0.01)\) and a 1-fold increase when compared with that of E₂-alone group \((P < 0.05)\). Because neither LNG nor MPA induced a rise in PCNA, CDC2, or BrdU incorporation when administered in the absence of E₂, we determined whether the rise in BrdU induced by these progestins in the presence of E₂ was associated with an increase in apoptosis.

To address this issue, analysis of cell viability and apoptosis were conducted. Indicators of cell viability were expression of mitochondrial ATP synthase subunit CVα expression and Bax/Bcl-2 ratio (Fig. 6, C and D). Consistent with previous analyses, E₂ increased cell viability by promoting mitochondrial function and reducing oxidative damage \((26)\), E₂ significantly increased CVα protein expression relative to vehicle control (Fig. 6C). E₂+P₄ significantly increased CVα expression comparable with that of E₂-alone group, whereas E₂+Nestorone and E₂+LNG significantly decreased CVα protein expression relative to E₂ alone. Remarkably, E₂+MPA significantly reduced CVα expression below that expressed in response to either vehicle or E₂ \((P < 0.05\) and \(P < 0.01\), respectively) (Fig. 6C). In parallel, E₂ significantly decreased the apoptosis indicator Bax/Bcl-2 ratio, whereas E₂+Nestorone, or LNG or MPA, increased the Bax/Bcl-2 ratio relative to E₂ alone, although the increase did not exceed the vehicle (Fig. 6D). These results are consistent with previous reports from our group and others indicating a lack of synergy in the neuroprotective effects when P₄ and E₂ were administered in combination \((18, 27)\) and that MPA could inhibit E₂-induced neuroprotective effect by antagonizing E₂-induced attenuation of intracellular calcium concentration \((5, 18, 21)\).

The rise in the Bax/Bcl2 ratio relative to E₂ suggested the potential of an apoptotic effect. To determine whether a rise in apoptosis paralleled the rise in Bax/Bcl2 ratio, TUNEL labeling was performed to identify apoptotic nuclei in response to different treatments of E₂ and progestins (Fig. 6E), and TUNEL+ cell numbers were detected via flow cytometry analysis. Results of the FACS analysis indicated that treatment with either E₂ alone, E₂+P₄, or E₂+Nestorone had no effect on TUNEL+ cell number relative to vehicle-treated animals. In contrast, E₂+LNG induced a 4- and a 2-fold increase in the number of TUNEL+ cells relative to vehicle and E₂-alone group, respectively \((P < 0.01\) and \(P < 0.05\)). The magnitude of TUNEL+ cells was maximal in the hippocampi derived...
from E2+MPA-treated animals. E2+MPA-treated animals exhibited an 8- and a 4-fold increase in TUNEL + cell count relative to vehicle and E2-alone group, respectively ($P < 0.01$ and $P < 0.01$). This is consistent with the pro-apoptotic effect of LNG and MPA in the uterus (23–25). Collectively, these data indicate that clinical progestins can exert significantly different outcomes on the survival of proliferating NPCs in vivo.
Consistent with our previous findings (7), proliferation induced by clinical progestins was dependent on the ERK signaling pathway and independent of nPR binding affinity as evidenced by further SAR analysis. Interestingly, MPA-induced inhibition of cell proliferation was not dependent on MAPK/ERK signaling pathway, because co-administration of UO126 had no impact on MPA-induced inhibition. This could be explained by our previous finding that MPA-induced pERK is not translocated to the nucleus (18, 28), indicating that signaling pathways other than the ERK may mediate the inhibitory effect of MPA.

A likely PR candidate for mediating rNPC proliferation is the membrane-associated PGRMC-1. Our previous report demonstrated that P4 significantly increased rNPC proliferation in a PGRMC-1 and MAPK-dependent manner (7). SAR analysis highlighted several critical structures for their proliferative efficacy of clinical progestins, and those structural features revealed no clear association with other binding affinity to nPR. The lack of an effect of the pure nPR agonist ORG 31710 supports the postulate that nPR was not the mediator of the proliferative effect of progestins. It is possible, however, that the proliferative effects of the progestins were combined effects of binding to multiple receptors rather than one. Indeed, as reported herein and by others, LNG and NGM exerts androgenic effects by binding to and activating the nuclear AR. However, NGM in contrast with LNG inhibited nuclear translocation of the AR, revealing an antiandrogenic property (29). Also norethynodrel induces estrogenic activity through aromatization in vivo. Although Noretorone can bind to the nuclear GR, it showed no glucocorticoid activity in vivo (16, 30, 31). In addition, nPR is expressed in the dentate gyrus of hippocampus, and activation of nPR by P4 is known to inhibit cell proliferation under various conditions (1). Further, the effects of progestins on glial cell population and potential glial-neuronal cross talk remained undetermined.

An increase in neural responses induced by selected progestins was also evident in vivo. Consistent with their in vitro proliferative effects, P4 and Noretorone significantly increased cell cycle protein expression and BrdU+ cell number in FACS analyses compared with vehicle-treated animals. The profile for LNG was consistent in that LNG failed to increase PCNA/CDC2 expression or total BrdU+ cell number as determined by FACS analysis. Although the lineage of the newly generated cells remains to be determined, these data provide preclinical evidence that clinically relevant progestins could significantly impact the regenerative capability of the brain.

The in vitro and in vivo neuroprotective effect of P4 has been reported by multiple groups (2, 4, 5, 20). Results from the current analyses extend these findings to now include up-regulation of a key marker of mitochondrial function and
cell viability in vivo. Further, our results demonstrate that clinically relevant progestins can differentially regulate neuron survival and viability. In vitro, norethynodrel, Nestorone, and LNG protected rat primary hippocampal neurons against glutamate-induced toxicity, whereas NGM, NET, and MPA exerted no significant effect. The lack of neuroprotective capability of MPA is consistent with our previous report (18, 32). In vivo analyses confirmed that P₄, Nestorone, and LNG induced a significant rise in CVα expression, whereas MPA showed no effect, indicating the neuroprotective effects of the progestins are closely related to their ability in regulating mitochondria function. In addition, only LNG and MPA significantly increased Bax/Bcl-2 ratio, which is consistent with previous report that P₄ does not directly regulate apoptosis, whereas both LNG and MPA induce a proapoptotic effect in the uterus (23–25).

Combined E₂ and clinical progestin regulation of neurogenic activity and cell viability

It is well documented that E₂ promotes neurogenesis and protection against neurodegenerative insults (33). Reported here, 30 μg/kg BW E₂ significantly increased both PCNA expression level and BrdU + cell number at a magnitude comparable with that of P₄ alone. No significant differences were observed between E₂-alone, E₂+P₄, and E₂+Nestorone group. This is in contrast with previous reports from Tanapat et al. (27), where P₄ administration subsequent to estradiol exposure decreased the amplitude of E₂-induced increase in BrdU + cell count. However, this could be explained by the differences in the treatment paradigm; Tanapat et al. (27) used chronic E₂ exposure followed by P₄ administration, whereas in our study, E₂ and P₄ treatment administration was acute and simultaneous. Further, there was no synergy in E₂+P₄-induced response compared with E₂ or P₄ alone. This is consistent with our previous report of a lack of synergy when P₄ and E₂ were administered in combination (18, 28).

Both LNG and MPA increased BrdU + cell count when administered in combination with E₂. However, in parallel to the increase in BrdU + cells, LNG and MPA significantly increased the number of TUNEL + cells indicative of increased apoptosis, which is consistent with the proapoptotic effects of LNG and MPA in the uterus (23, 24). Although the phenotype of the apoptotic cells remains unidentified at this point, it is probable that the increase of TUNEL + cell population reflects the premature death of the newly generated cells (BrdU + cells).

Therapeutic implications of progestin regulation of neural proliferation and viability

Clinical progestins are an integral constituent of oral contraceptive therapy, progestin-only contraception, fertility therapy, and postmenopausal hormone therapies. Progestin containing contraceptives account for an increasing proportion of modern contraceptive formulations used by women around the world. In the United Kingdom, the progestins mainly used are 19-nortestosterone derivatives (NET, norgestrel, and LNG) (8, 34). In France, micronized P₄ and 19-norprogesterone (such as promegestone and nomegestrol acetate) are commonly prescribed, whereas MPA is the most prescribed progestin in the United States and the progestin used in commonly randomized controlled hormone therapy trials including the Women’s Health Initiative (35) and Women’s Health Initiative Memory Study (36). Typically, clinical progestins are chronically administered extending over many years to decades. For example, depomedroxyprogesterone acetate, a long-acting formulation of MPA, is extensively prescribed for adolescent females (37), and Norplant implant delivers constant infusion of LNG for 5–7 yr (38). Although data contained herein are derived from acute in vitro and in vivo exposures, our emergent findings suggest that chronic use could have long-term implications for neural function, regenerative capacity, and viability. Although the impact of chronic exposure to clinical progestins remains undetermined, the acute in vivo data indicate that P₄ and Nestorone have potential beneficial outcomes for inducing and sustaining regenerative capacity of the brain. In contrast, LNG and MPA could have potential adverse outcomes on regenerative capacity of the brain.

Collectively, results of these preclinical translational analyses indicate that clinical progestins vary dramatically in their impact on the regenerative capacity of the brain and thus are likely to have clinical implications for long-term neurological function.

Acknowledgments

We thank Dr. Ronald Irwin, Zisu Mao, and Syeda Ahmed for their contributions.

Address all correspondence and requests for reprints to: Roberta Diaz Brinton, Ph.D., Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, California 90089. E-mail: rbrinton@usc.edu.

This work was supported by National Institute on Aging Grant 1 PO1 AG026572, Project 3 of Progesterone in Brain Aging and Alzheimer’s Disease Program Project (to R.D.B.).

References


